Mablink Bioscience S.A.S.: Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy
Emergence Therapeutics obtains the rights to develop a novel antibody-drug conjugate using Mablink Bioscience's proprietary PSARlink drug-linker technology. Mablink Bioscience S.A.S. a biotechnology
Nordrhein Westfalen Jean Guillaume Lafay Kostenloser Wertpapierhandel Marc Lopez Mablink Bioscience Marseille Universit
Source: finanznachrichten.de